Eileen Hu

1.1k total citations
11 papers, 213 citations indexed

About

Eileen Hu is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Eileen Hu has authored 11 papers receiving a total of 213 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Eileen Hu's work include Chronic Lymphocytic Leukemia Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Eileen Hu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Eileen Hu collaborates with scholars based in United States. Eileen Hu's co-authors include Christopher J. Ott, Johannes Kreuzer, Michael S. Lawrence, Wilhelm Haas, Xcanda Ixchel Herrera Lopez, Raghu Vannam, Robert Morris, Ron Weiss, Breanna DiAndreth and Noreen Wauford and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Eileen Hu

11 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eileen Hu United States	6	141	50	36	28	26	11	213
Shlomzion Aumann Israel	7	97 0.7×	51 1.0×	53 1.5×	33 1.2×	9 0.3×	25	160
Yasuhiro Kazuma Japan	6	93 0.7×	55 1.1×	21 0.6×	17 0.6×	22 0.8×	15	165
Nicole Nasholm United States	10	91 0.6×	82 1.6×	30 0.8×	10 0.4×	56 2.2×	17	183
Aurore Crétien France	5	215 1.5×	42 0.8×	18 0.5×	20 0.7×	15 0.6×	6	260
Long Kwei United States	8	48 0.3×	62 1.2×	36 1.0×	16 0.6×	52 2.0×	16	215
David Szeto United States	5	63 0.4×	37 0.7×	77 2.1×	53 1.9×	21 0.8×	6	174
Hideharu Muto Japan	5	70 0.5×	46 0.9×	57 1.6×	24 0.9×	51 2.0×	16	160
Stefan Köhrer Austria	4	69 0.5×	42 0.8×	32 0.9×	41 1.5×	30 1.2×	11	153
María Abáigar Spain	7	82 0.6×	25 0.5×	90 2.5×	44 1.6×	12 0.5×	16	150

Countries citing papers authored by Eileen Hu

Since Specialization

Citations

This map shows the geographic impact of Eileen Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen Hu more than expected).

Fields of papers citing papers by Eileen Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen Hu. The network helps show where Eileen Hu may publish in the future.

Co-authorship network of co-authors of Eileen Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen Hu. A scholar is included among the top collaborators of Eileen Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen Hu. Eileen Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

DiAndreth, Breanna, Noreen Wauford, Eileen Hu, Sebastian Palacios, & Ron Weiss. (2022). PERSIST platform provides programmable RNA regulation using CRISPR endoRNases. Nature Communications. 13(1). 2582–2582. 23 indexed citations

Vannam, Raghu, Eileen Hu, Johannes Kreuzer, et al.. (2021). Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology. 28(4). 503–514.e12. 102 indexed citations

Hu, Eileen, James S. Blachly, Caner Saygin, et al.. (2020). LC-FACSeq is a method for detecting rare clones in leukemia. JCI Insight. 5(12). 3 indexed citations

Walker, Logan A., Michael G. Sovic, Chi‐Ling Chiang, et al.. (2020). CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq. Journal of Translational Medicine. 18(1). 63–63. 7 indexed citations

Hu, Eileen, et al.. (2020). Mobile Apps for Professional Dermatology Education: An Objective Review. Cutis. 106(6). 321–325. 2 indexed citations

Long, Meixiao, Carolyn Cheney, Eileen Hu, et al.. (2019). Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity. Blood. 134(Supplement_1). 1049–1049. 3 indexed citations

Momper, Lily, et al.. (2019). Metabolic versatility in a modern lineage of cyanobacteria from terrestrial hot springs. Free Radical Biology and Medicine. 140. 224–232. 10 indexed citations

Hu, Eileen, Priscilla Do, Rajeswaran Mani, et al.. (2019). Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia. Cancer Research. 79(13_Supplement). 1541–1541. 1 indexed citations

Dong, Shuai, Bonnie K. Harrington, Eileen Hu, et al.. (2018). PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. Journal of Clinical Investigation. 129(1). 122–136. 37 indexed citations

10.

Hu, Eileen, Priscilla Do, Rajeswaran Mani, et al.. (2017). Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. Blood. 130. 3017–3017. 1 indexed citations

11.

Tyler, Kelly, Bradley M. Haverkos, Eileen Hu, et al.. (2015). The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Frontiers in Oncology. 5. 136–136. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact